Skip to content

Clinical Study on the Effectiveness and Safety of Remazolam in Patients with Severe Pneumonia and Invasive Mechanical Ventilation

Clinical Study on the Effectiveness and Safety of Remazolam in Patients with Severe Pneumonia and Invasive Mechanical Ventilation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045922
Enrollment
Unknown
Registered
2021-04-28
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Pneumonia

Interventions

Group A:Remazolam sedation
Group B:Midazolam sedation
Group C:Propofol sedation

Sponsors

The Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for severe pneumonia (IDSA/ATS diagnostic criteria); 2. Aged > 18 years; 3. Required invasive mechanical ventilation.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Chronic moderate to severe renal dysfunction (Scr > 178umol/l, urea nitrogen > 9mmol/l) and liver function abnormalities (Child-Pugh C); 3. Patients with pre-existing dementia or obvious stroke sequelae, and patients with craniocerebral trauma that cannot be assessed; 4. Allergic to opioids and benzodiazepines; 5. Long-term use of benzodiazepines; 6. Severe circulatory instability when transferred to ICU, requiring high-dose vasopressor maintenance; 7. Post-cardiopulmonary resuscitation.

Design outcomes

Primary

MeasureTime frame
Sedation compliance rate;

Secondary

MeasureTime frame
Mechanical ventilation time;tracheal intubation time;Vital signs(blood pressure, heart rate, respiration);liver function;kidney function;Dosage of sedative and analgesic drugs;Incidence of delirium;

Countries

China

Contacts

Public ContactCheng Yumei

The Affiliated Hospital of Guizhou Medical University

64960877@qq.com+86 13984055322

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026